Actemra Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis –Associated Lymphoproliferative Disorders
ConclusionAntirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time. Furthermore, TCZ-only regimens are recommended after LPD onset. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - March 13, 2024 Category: Rheumatology Authors: Yoshihiko Hoshida, Atsuko Tsujii, Shiro Ohshima, Yukihiko Saeki, Masato Yagita, Tomoya Miyamura, Masao Katayama, Tomonori Kawasaki, Yasushi Hiramatsu, Hisaji Oshima, Toshihiko Murayama, Shinji Higa, Kazuya Kuraoka, Fuminori Hirano, Kenji Ich Tags: Full Length Source Type: research

Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study): a multicenter, post-marketing, non-interventional, observational trial
ConclusionsThe current study confirms the favorable safety and effectiveness of TCZ-SC as well as its acceptability by RA patients in Greece, with sustained high persistence rates up to 52 weeks. TCZ-SC offers a sustainable treatment response in RA.Key Points•Based upon clinical and patient-reported outcomes, TCZ-SC is a highly effective and safe treatment modality in patients with moderate-to-severe RA.•Persistence to TCZ-SC was high throughout the study, both as monotherapy and in combination with csDMARDs.•TCZ-SC is effective both as monotherapy and when used in combination with other csDMARDs regardless of the ...
Source: Clinical Rheumatology - March 12, 2024 Category: Rheumatology Source Type: research

Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
AbstractBackgroundOcular inflammatory diseases, including scleritis and uveitis, have been widely treated with immunomodulatory therapies (IMTs) as a steroid-sparing approach. Such strategy includes conventional therapies (antimetabolites, alkylating agents, and calcineurin inhibitors) as well as biologic agents like adalimumab, infliximab, rituximab, and tocilizumab. Cyclophosphamide (CP) is an alkylating agent and mainly inhibits the functioning of both T and B cells. Though known to have potential adverse events, including bone marrow suppression, hemorrhagic cystitis, and sterility, CP has been shown to be efficacious,...
Source: Journal of Ophthalmic Inflammation and Infection - March 11, 2024 Category: Opthalmology Source Type: research

Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
This study utilized a meta-analysis approach to compare the CRS profile in BCMA-targeting CAR-T vs. BsAb immunotherapies administered either i.v. or s.c. in patients with RRMM. A total of 36 studies including 1,560 patients with RRMM treated with BCMA-targeting CAR-T and BsAb therapies were included in the analysis. The current analysis suggests that compared with BsAbs, CAR-T therapies were associated with higher CRS incidences (88% vs. 59%), higher rates of grade ≥ 3 CRS (7% vs. 2%), longer CRS duration (5 vs. 2 days), and more prevalent tocilizumab use (44% vs. 25%). The proportion of CRS grade ≥ 3 may also be lower...
Source: Clinical Pharmacology and Therapeutics - March 9, 2024 Category: Drugs & Pharmacology Authors: Pooneh Soltantabar Sheena Sharma Diane Wang Hoi-Kei Lon Akos Czibere Anne Hickmann Mohamed Elmeliegy Source Type: research

An Autopsy Case of COVID-19 with New Diffuse Pulmonary Ossification
We present the case of a 61-year-old man who developed Coronavirus disease 2019 (COVID-19) and died during treatment for relapsing polychondritis. The patient was intubated and treated with steroid pulse therapy, remdecivir, antibacterial agents, baricitinib, and tocilizumab. However, his respiratory condition worsened, and he died 108 days after disease onset. An autopsy revealed diffuse alveolar damage in the fibrotic phase in all lung lobes, diffuse pulmonary ossification, and cytomegalovirus-infected cells in the middle lobe of the right lung. We herein discuss the clinical features and pathological findings of COVID-1...
Source: Internal Medicine - March 3, 2024 Category: Internal Medicine Authors: Taisuke Nakagawa Yasuaki Kotetsu Katsumi Takizawa Michihiro Yoshimi Isamu Okamoto Shohei Takata Source Type: research